Mereo Biopharma Group Plc ADR (NASDAQ:MREO) has a beta value of 0.48 and has seen 1.65 million shares traded in the last trading session. The company, currently valued at $359.95M, closed the last trade at $2.32 per share which meant it lost -$0.18 on the day or -7.20% during that session. The MREO stock price is -116.38% off its 52-week high price of $5.02 and 31.9% above the 52-week low of $1.58.
The consensus among analysts is that Mereo Biopharma Group Plc ADR (MREO) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Sporting -7.20% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MREO stock price touched $2.32 or saw a rise of 9.02%. Year-to-date, Mereo Biopharma Group Plc ADR shares have moved -33.71%, while the 5-day performance has seen it change -0.43%. Over the past 30 days, the shares of Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have changed 18.97%.
Wall Street analysts have a consensus price target for the stock at $7.5, which means that the shares’ value could jump 69.07% from current levels. The projected low price target is $4.0 while the price target rests at a high of $8.0. In that case, then, we find that the current price level is -244.83% off the targeted high while a plunge would see the stock gain -72.41% from current levels.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
The company’s shares have lost -43.28% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.82% over the past 5 years. Earnings growth for 2025 is a modest 33.33% while over the next 5 years, the company’s earnings are expected to increase by 20.63%.
MREO Dividends
Mereo Biopharma Group Plc ADR is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
The top two institutional holders are RUBRIC CAPITAL MANAGEMENT LP with over 15.31 million shares worth more than $55.11 million. As of 2024-06-30, RUBRIC CAPITAL MANAGEMENT LP held 2.1506% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.79 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.45 million and represent 1.6566% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF . As of Mar 31, 2025 , the former fund manager holds about 0.48% shares in the company for having 759.1 shares of worth $1.76 million while later fund manager owns 267.46 shares of worth $0.62 million as of Feb 28, 2025 , which makes it owner of about 0.17% of company’s outstanding stock.
